Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Performance - Skye Bioscience's lead product candidate, nimacimab, reportedly did not meet the primary weight-loss endpoint in a Phase 2a study, leading to a significant drop in share price [4]. - Following the announcement of the study results, Skye's share price fell by 60%, decreasing from $4.75 to $1.90 per share [4]. Group 3: Company Background - Skye Bioscience is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2].

Group 1 - A class action lawsuit has been filed against Jayud Global Logistics Limited on behalf of investors who acquired Jayud securities between April 21, 2023, and April 30, 2025 [1][2] - Jayud, headquartered in Shenzhen, China, offers global cross-border supply chain solutions, including freight forwarding and logistics IT systems [2] - During the Class Period, Jayud's stock price allegedly surged from approximately $1.00 to nearly $8.00 per share, attributed to a fraudulent "pump-and-dump" scheme, before collapsing by about 95% on April 2, 2025 [3] Group 2 - Investors who purchased Jayud securities during the Class Period have until January 20, 2026, to seek appointment as lead plaintiff [2] - Berger Montague, the law firm representing the plaintiffs, is recognized for its expertise in complex civil litigation and has recovered over $50 billion for clients over its 55-year history [5]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Developments - On November 14, 2025, Anavex announced a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the Marketing Authorisation Application (MAA) for blarcamesine [3]. - Following this announcement, Anavex's stock price dropped by $2.05 per share, representing a decline of 35.94%, closing at $3.65 per share on the same day [3]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for the rights of victims of securities fraud and corporate misconduct [4]. - The firm has a track record of recovering multimillion-dollar damages awards for class members [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Ultragenyx Pharmaceutical Inc. and its officers or directors, following disappointing Phase 3 study results for setrusumab, which led to a significant drop in the company's stock price [1][3][4]. Group 1: Company Performance - Ultragenyx announced results from two Phase 3 studies for setrusumab, a treatment for bone metabolism conditions, on December 29, 2025 [3]. - Neither study achieved statistical significance for the primary endpoints related to the reduction in annualized clinical fracture rate compared to placebo or bisphosphonates [3]. - Both studies met their secondary endpoints, showing significant improvements in bone mineral density against comparators [3]. Group 2: Stock Market Reaction - Following the announcement of the study results, Ultragenyx's stock price fell by $2.02 per share, representing a decline of 87.64%, closing at $0.28 per share on December 29, 2025 [4]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud by Ultragenyx and its management [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) for alleged violations of federal securities laws during the Class Period from July 25, 2025, to August 14, 2025, due to misleading statements regarding the company's business and operations [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased SLM securities during the specified Class Period [2]. - The Complaint alleges that SLM's management made materially false and misleading statements that inflated the prices of SLM's securities [3]. - Specific allegations include a significant increase in early-stage delinquencies, overstated effectiveness of loss mitigation and loan modification programs, and misleading impressions about the company's overall stability [3]. Group 2: Next Steps for Investors - Investors affected by the alleged misconduct have until February 17, 2026, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ventyx Biosciences, Inc. and its officers or directors [1]. Group 1: Company Developments - On December 2, 2025, Ventyx announced a revision of its guidance for topline data release from the interim analysis of its Phase 2 study of VTX2735, now expected in Q1 2026 [3]. - The CEO indicated that this shift allows for the introduction of dose-ranging studies with a new once-daily formulation and expansion into Canada, the EU, and the UK, which is believed to accelerate Phase 3 timelines [3]. - Following this announcement, Ventyx's stock price decreased by $1.44 per share, or 15.35%, closing at $7.94 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Ventyx to discuss claims related to potential securities fraud [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc on behalf of investors who acquired Klarna securities during the specified class period, alleging that the company failed to disclose material financial risks in its IPO documents [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Klarna underestimated the likelihood of rising loss reserves shortly after its IPO, which is linked to the high-risk profiles of its customers [3]. - Investors who purchased Klarna securities during the class period have until February 20, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Financial Impact - Following a report on November 18, 2025, that Klarna had set aside greater provisions for credit losses than anticipated, the company's share price declined by 21% from the IPO price of $40 to $31.31 [4].

NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Integer Holdings Corporation ("Integer Holdings Corporation" or the "Company") (NYSE: ITGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integer Holdings Corporation investors who were adversely affected by alleged securities fraud between July 25, 2024 and October 22, 2025. Follow the link below to get more information and be contacted by a member of our team: http ...

Core Viewpoint - Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against B. Riley Financial, Inc. (now BRC Group Holdings, Inc.) due to alleged false statements regarding a $200 million loan to an entity linked to Brian Kahn, who pleaded guilty to conspiracy to commit securities fraud [1][2]. Group 1: Legal Proceedings - A U.S. District Judge ruled that key claims in a securities fraud lawsuit against B. Riley and its co-CEO Bryant Riley will proceed, alleging that the company misled investors by not disclosing a $200.5 million loan to Vintage Capital Management, LLC, controlled by Kahn [2]. - The lawsuit claims that misleading statements caused B. Riley's stock to trade at artificially inflated prices, with the stock price dropping from over $72 in March 2022 to below $6 by November 2024 after the truth about the loan was revealed [2]. Group 2: Investigations - The firm is investigating potential wrongdoing by B. Riley's directors and officers in connection with the allegations of misleading investors [3]. - The U.S. Securities and Exchange Commission has subpoenaed documents related to B. Riley's dealings with Kahn, indicating a broader investigation into the company's practices [2].

Core Viewpoint - A class action securities lawsuit has been filed against DeFi Technologies, alleging securities fraud that affected investors between May 12, 2025, and November 14, 2025 [1]. Group 1: Allegations of Fraud - The lawsuit claims that DeFi Technologies faced delays in executing its DeFi arbitrage strategy, which was a key revenue driver for the Company [2]. - It is alleged that DeFi Technologies understated the competition from other digital asset treasury companies, impacting its ability to execute its DeFi arbitrage strategy [2]. - The complaint states that due to these issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025 [2]. - Defendants are accused of downplaying the negative impact of these issues on DeFi Technologies' business and financial results, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses in DeFi Technologies during the relevant time frame have until January 30, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].